$211,409,788

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to EMERGENT BIODEFENSE OPERATIONS LANSING LLC

biotechactiveONGOING · MOD OF 2022 CONTRACT

WORK BEGAN2022-08-29·LATEST ACTION2026-04-21·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50122C00047_7505_-NONE-_-NONE-

Award description

CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Latest obligation on a 2022 smallpox antiviral research contract with Emergent Biodefense, supporting development of medical countermeasures.

Sub-sectors

antiviral-developmentsmallpox-countermeasurebiodefense

Why this matters

Smallpox antivirals are critical biodefense assets; this ongoing program ensures U.S. capacity to respond to potential biological threats.

Supply-chain signal

Supports domestic pharmaceutical manufacturing and R&D infrastructure for pandemic/biodefense preparedness.

U.S.–China competition angle

Biodefense antiviral development is strategically important as adversaries develop biological capabilities; U.S. countermeasure readiness is a deterrent.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-21. Cost: $0.003048.

Period of performance

Start

2022-08-29

End

2028-10-01

Status

activein 824 days

Recipient

EMERGENT BIODEFENSE OPERATIONS LANSING LLC

UEI JLLWGQX6LNA5

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00047_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.